Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an ...

Oculis Holding completes enrollment in both DIAMOND phase 3 clinical trials of OCS-01 in diabetic macular edema: Zug, Switzerland Monday, April 14, 2025, 15:00 Hrs [IST] Oculis Ho ...

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients randomized ...

Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion: Berlin Thursday, April 10, 2025, 16:00 Hrs [IST] Bayer has submitted an application to the E ...

A 43-year-old woman presented with 6 months of recurrent bilateral eye pain and redness alongside spontaneous urticaria.She ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

To attend the event or participate virtually, please register here. The event will provide an update on Oculis’ portfolio of three innovative late-stage clinical candidates, offer further details on ...

Iridex Corporation (Nasdaq:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure ...

Pars plana vitrectomy is a safe and effective surgery that is essential in the treatment of a variety of posterior segment ...

Adverum Biotechnologies, Inc.’s ADVM share price has surged by 7.87%, which has investors questioning if this is right time to sell.